MedTrace Logo

Amantadine Therapy for Cognitive Impairment in Long COVID

NCT06055244 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-01-27

No results posted yet for this study

Summary

This study will look at the effects of amantadine on cognitive function in persons with Long COVID. It will also collect specimens to study possible causes of cognitive symptoms in Long COVID, and whether any lab tests can predict who will respond better to amantadine.

Conditions

  • Long COVID
  • Post-COVID19 Condition
  • Post-Acute COVID19 Syndrome

Interventions

DRUG

Amantadine

Subjects will be give amantadine 100 mg twice daily.

Sponsors & Collaborators

  • Ohio State University

    lead OTHER

Principal Investigators

  • Andrew I Schamess, MD · Ohio State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-07
Primary Completion
2025-12-11
Completion
2025-12-29
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06055244 on ClinicalTrials.gov